KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) EPS (Basic) (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed EPS (Basic) for 15 consecutive years, with -$0.07 as the latest value for Q4 2025.

  • Quarterly EPS (Basic) fell 125.0% to -$0.07 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$0.68 through Dec 2025, down 150.75% year-over-year, with the annual reading at -$0.68 for FY2025, 150.75% down from the prior year.
  • EPS (Basic) for Q4 2025 was -$0.07 at Supernus Pharmaceuticals, up from -$0.8 in the prior quarter.
  • The five-year high for EPS (Basic) was $0.7 in Q3 2024, with the low at -$0.8 in Q3 2025.
  • Average EPS (Basic) over 5 years is $0.14, with a median of $0.13 recorded in 2022.
  • The sharpest move saw EPS (Basic) surged 1900.0% in 2024, then plummeted 8147.81% in 2025.
  • Over 5 years, EPS (Basic) stood at $0.05 in 2021, then surged by 840.0% to $0.47 in 2022, then crashed by 95.74% to $0.02 in 2023, then soared by 1300.0% to $0.28 in 2024, then plummeted by 125.0% to -$0.07 in 2025.
  • According to Business Quant data, EPS (Basic) over the past three periods came in at -$0.07, -$0.8, and $0.4 for Q4 2025, Q3 2025, and Q2 2025 respectively.